Key Highlights

  • 0.19 is the per-share loss projected for Immix Biopharma, Eledon and Neumora in the screener snapshot, compared with 0.95 at Immunic and 2.35 at Inhibrx, and only Neumora is valued below USD 100 million.
  • 232.1 million is Immix's USD cash on June 30, 2026, topping USD 219.5 million at Inhibrx on August 6, 2026, USD 155.1 million at Immunic, USD 116.8 million at Neumora and USD 88.8 million at Eledon.
  • 2027 is the pivotal funding horizon, since Immix guides to roughly mid-2028, Immunic to late 2027, Neumora to third-quarter 2027 and Eledon to second-quarter 2027.
  • 717.94 million is Immix's USD valuation in the snapshot, set against USD 1.33 billion at Inhibrx, USD 216.97 million at Eledon, USD 110.79 million at Immunic and USD 88.87 million at Neumora.

Inhibrx Biosciences, Inc. (NASDAQ:INBX): Deepest Loss Estimate at 2.35

Inhibrx Biosciences, Inc. (NASDAQ:INBX) will publish third quarter 2026 figures once trading ends on November 13, 2026. Analysts project a loss of 2.35 a share, the deepest among the five, and the screener snapshot lists a valuation of USD 1.33 billion. Last quarter's loss was USD 2.34 a share, or USD 36.7 million, across roughly 15.7 million weighted shares, while the company booked zero Revenue compared with USD 1.3 million in the year-ago quarter. R&D spending was USD 23.9 million, against USD 22.3 million. The ozekibart BLA was accepted in June 2026, setting an FDA goal date of April 14, 2027, while interim colorectal data arrive in first-quarter 2027. Put simply, Inhibrx pairs the widest projected loss with the largest valuation of the five. Inhibrx Biosciences, Inc. (NASDAQ:INBX) had USD 219.5 million in cash on August 6, 2026, yet it also reports a stockholders' Deficit of USD 53.0 million alongside USD 175.0 million in Loan principal, and it did not state a runway estimate.

Immix Biopharma, Inc. (NASDAQ:IMMX): Longest Runway, Guided to Mid-2028

Immix Biopharma, Inc. (NASDAQ:IMMX) will publish third quarter 2026 figures once trading ends on November 13, 2026. The consensus EPS estimate is -0.19, and the screener snapshot lists a valuation of USD 717.94 million. In the same quarter a year ago, the bottom-line loss was USD 7.59 million, or USD 0.24 a share. For the quarter ended June 30, 2026, a third-party analyst report put the operating loss at USD 12.5 million, with R&D of USD 5.33 million and G&A of USD 7.12 million. In the NEXICART-2 trial of NXC-201, 19 of 20 evaluable patients (95%) achieved a complete response. Management has signalled a BLA filing during first-half 2027 and one-year follow-up results in March 2027. Combined with its cash pile, this gives Immix the largest cash balance among the five. Immix Biopharma, Inc. (NASDAQ:IMMX) carries no debt, had USD 232.1 million in Liquidity and guides to funding lasting until about mid-2028, following a roughly USD 150 million gross raise in May 2026.

Eledon Pharmaceuticals (NASDAQ:ELDN): Transplant Data and a Shorter Runway

Eledon Pharmaceuticals (NASDAQ:ELDN) is slated to publish third quarter 2026 figures once trading ends on November 13, 2026. Analysts project a loss of 0.19 a share, and the screener snapshot lists a valuation of USD 216.97 million. Last quarter's loss was 0.27 a share, while the loss in third-quarter 2025 was 0.21 a share. R&D came to USD 18.2 million, G&A was USD 4.6 million and the bottom-line loss was USD 31.6 million. BESTOW results at 18 months showed a mean eGFR near 74 against 61 for tacrolimus, while a Phase 3 kidney transplant study of about 600 patients is slated for late 2026. Eledon Pharmaceuticals (NASDAQ:ELDN) had USD 88.8 million in cash, guides to funding reaching second-quarter 2027, and carries USD 40.0 million in Warrant liabilities capable of distorting reported results. In short, Eledon has the smallest cash balance among the five. Management gave no formal financial outlook, and 12 of 12 islet patients no longer needed insulin.

Immunic, Inc. (NASDAQ:IMUX): ENSURE Data Expected Before Year-End 2026

Immunic, Inc. (NASDAQ:IMUX) will publish third quarter 2026 figures ahead of the opening bell on November 13, 2026. The consensus EPS estimate is -0.95, and the screener snapshot lists a valuation of USD 110.79 million. Last quarter's loss was USD 0.80 a share, and the bottom-line loss in third-quarter 2025 was USD 25.6 million. R&D climbed to USD 25.9 million, G&A to USD 9.4 million and overall operating costs to USD 35.3 million. Management anticipates topline ENSURE data before year-end 2026, a US NDA in mid-2027 and approval targeted for 2028. Immunic, Inc. (NASDAQ:IMUX) had USD 155.1 million in cash on June 30, 2026, which by calculation tops its market worth by USD 44.3 million, and management foresees funding into late 2027. That cash balance exceeds what the stock market currently assigns to the entire company. Weighted shares were 42,513,839 against 13,217,520 a year before. Interest income was USD 1.3 million, up from USD 0.3 million, and the loss over six months was about USD 66.7 million.

Neumora Therapeutics, Inc. (NASDAQ:NMRA): Cost Cuts and a Micro-Cap Warning

Neumora Therapeutics, Inc. (NASDAQ:NMRA) will publish third quarter 2026 figures ahead of the opening bell on November 13, 2026. The consensus EPS estimate is -0.19, and the screener snapshot lists a valuation of USD 88.87 million. Below USD 100 million, small companies may prove volatile as well as thinly traded. Last quarter's loss was USD 0.23 a share, with a bottom-line loss of USD 43.1 million versus USD 52.7 million, R&D of USD 29.3 million versus USD 38.7 million and G&A of USD 12.9 million. Neumora Therapeutics, Inc. (NASDAQ:NMRA) had USD 116.8 million in cash, down from USD 182.5 million on December 31, 2025, and expects that to last into third-quarter 2027. Management intends to file an NMRA-215 IND during fourth-quarter 2026 and recently appointed Joshua Pinto as chief executive. Losses narrowed alongside lower R&D spending. The loss over six months was USD 96.5 million versus USD 120.7 million, and NMRA-511 data are likewise due during that period.

Where Things Stand

For Canadian investors sizing up the group: Inhibrx Biosciences, Inc. (NASDAQ:INBX) has a projected loss of 2.35 and an FDA goal date of April 14, 2027. Immix Biopharma, Inc. (NASDAQ:IMMX) has a projected loss of 0.19 and funding lasting to about mid-2028. Eledon Pharmaceuticals (NASDAQ:ELDN) shares that 0.19 estimate but has funding reaching only second-quarter 2027. Immunic, Inc. (NASDAQ:IMUX) has a 0.95 projected loss and awaits ENSURE data before year-end 2026. Neumora Therapeutics, Inc. (NASDAQ:NMRA) has a 0.19 projected loss and a USD 88.87 million valuation. No product revenue turned up for any of the five, so outcomes hinge on spending and funding. This piece is informational only.